APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

JD Health International  / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/jd-health-international" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> raised US$3.5bn in its Hong Kong IPO, priced at HK$70.58 per share, at the top-end of its price range.</p>
<p>JDH’s retail pharmacy and online healthcare services form a strong, closed loop, end-to-end healthcare ecosystem that is well-positioned to benefit from the digitalization of China’s healthcare system. It has an extensive network of online and offline pharmacies which is expanding into offering more online healthcare services. </p>
<p>In this note, we will look at the deal dynamics and provide a table with implied valuation at different share price levels.</p>
<p>We have previously covered the IPO extensively:</p>
<ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-well-positioned-to-ride-china-s-healthcare-digitalization" target="_blank" data-smartkarma-citation="insights:43711" rel="noopener">JD Health (京东健康) Pre-IPO - Well-Positioned to Ride China’s Healthcare Digitalization</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-peer-comparison-it-s-a-close-fight-and-competition-is-intensifying" target="_blank" data-smartkarma-citation="insights:45062" rel="noopener">JD Health (京东健康) Pre-IPO - Peer Comparison - It's a Close Fight and Competition Is Intensifying</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-assumptions-and-valuations" target="_blank" data-smartkarma-citation="insights:45266" rel="noopener">JD Health (京东健康) Pre-IPO - Assumptions and Valuations</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-updates-from-phip-fine-tuning-forecasts" target="_blank" data-smartkarma-citation="insights:45368" rel="noopener">JD Health (京东健康) Pre-IPO - Updates from PHIP - Fine-Tuning Forecasts</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-ipo-paying-to-ride-the-early-innings-of-healthcare-transformation" target="_blank" data-smartkarma-citation="insights:45695" rel="noopener">JD Health (京东健康) IPO - Paying to Ride the Early Innings of Healthcare Transformation</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-ipo-ali-health-1h-results-read-through-and-index-inclusions" target="_blank" data-smartkarma-citation="insights:45773" rel="noopener">JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions</a> </li>
</ul>

JD Health (6618 HK) raised US$3.5bn in its Hong Kong IPO, priced at HK$70.58 per share, at the top-end of its price range.
JDH’s retail pharmacy and online healthcare services form a strong, closed loop, end-to-end healthcare ecosystem that is well-positioned to benefit from the digitalization of China’s healthcare system. It has an extensive network of online and offline pharmacies which is expanding into offering more online healthcare services. 
In this note, we will look at the deal dynamics and provide a table with implied valuation at different share price levels.
We have previously covered the IPO extensively:


JD Health (京东健康) Pre-IPO - Well-Positioned to Ride China’s Healthcare Digitalization 

JD Health (京东健康) Pre-IPO - Peer Comparison - It's a Close Fight and Competition Is Intensifying 

JD Health (京东健康) Pre-IPO - Assumptions and Valuations 

JD Health (京东健康) Pre-IPO - Updates from PHIP - Fine-Tuning Forecasts 

JD Health (京东健康) IPO - Paying to Ride the Early Innings of Healthcare Transformation 

JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions 


JD Health (京东健康) IPO Trading - Looking to Be a Solid Debut

<p><a href="https://www.smartkarma.com/entities/jd-health-international" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> (JDH) is looking to raise up to US$3.47bn in its upcoming Hong Kong IPO </p><p>JDH’s retail pharmacy and online healthcare services form a strong, closed loop, end-to-end healthcare ecosystem that is well-positioned to benefit from the digitalization of China’s healthcare system. It has an extensive network of online and offline pharmacies which is expanding into offering more online healthcare services. Revenue has been strong in the past three years and it has accelerated further due to COVID-19. </p><p>In this note, we will take a look at Ali Health’s 1H FY2020 results and the prospects of fast track/ early inclusion into various indices.</p><div><p>Our previous coverage of the IPO:</p></div><div><ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-well-positioned-to-ride-china-s-healthcare-digitalization" target="_blank" data-smartkarma-citation="insights:43711" rel="noopener">JD Health (京东健康) Pre-IPO - Well-Positioned to Ride China’s Healthcare Digitalization</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-peer-comparison-it-s-a-close-fight-and-competition-is-intensifying" target="_blank" data-smartkarma-citation="insights:45062" rel="noopener">JD Health (京东健康) Pre-IPO - Peer Comparison - It's a Close Fight and Competition Is Intensifying</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-assumptions-and-valuations" target="_blank" data-smartkarma-citation="insights:45266" rel="noopener">JD Health (京东健康) Pre-IPO - Assumptions and Valuations</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-updates-from-phip-fine-tuning-forecasts" target="_blank" data-smartkarma-citation="insights:45368" rel="noopener">JD Health (京东健康) Pre-IPO - Updates from PHIP - Fine-Tuning Forecasts</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-ipo-paying-to-ride-the-early-innings-of-healthcare-transformation" target="_blank" data-smartkarma-citation="insights:45695" rel="noopener">JD Health (京东健康) IPO - Paying to Ride the Early Innings of Healthcare Transformation</a> </li>
</ul></div>

JD Health (6618 HK) (JDH) is looking to raise up to US$3.47bn in its upcoming Hong Kong IPO JDH’s retail pharmacy and online healthcare services form a strong, closed loop, end-to-end healthcare ecosystem that is well-positioned to benefit from the digitalization of China’s healthcare system. It has an extensive network of online and offline pharmacies which is expanding into offering more online healthcare services. Revenue has been strong in the past three years and it has accelerated further due to COVID-19. In this note, we will take a look at Ali Health’s 1H FY2020 results and the prospects of fast track/ early inclusion into various indices.Our previous coverage of the IPO:

JD Health (京东健康) Pre-IPO - Well-Positioned to Ride China’s Healthcare Digitalization 

JD Health (京东健康) Pre-IPO - Peer Comparison - It's a Close Fight and Competition Is Intensifying 

JD Health (京东健康) Pre-IPO - Assumptions and Valuations 

JD Health (京东健康) Pre-IPO - Updates from PHIP - Fine-Tuning Forecasts 

JD Health (京东健康) IPO - Paying to Ride the Early Innings of Healthcare Transformation 


JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

<p>Healthcare’s presence in Asian capital markets has increased substantially over the last four years on the heels of substantial investments in private markets (VC/PE). Policy reforms and changes in listing rules, most notably in China, have led to an explosion of market cap creation for the sector as the universe of companies has expanded to include innovative companies, most notably pre-revenue biopharmaceutical companies. At the same time, substantial investments in digital healthcare, fueled by the COVID-19 pandemic, adds a new source of listed companies. This Insight focuses on leading unlisted healthcare companies in China, India, and ASEAN that have raised substantial amounts of capital and appear to be candidates for listing.   </p>

Healthcare’s presence in Asian capital markets has increased substantially over the last four years on the heels of substantial investments in private markets (VC/PE). Policy reforms and changes in listing rules, most notably in China, have led to an explosion of market cap creation for the sector as the universe of companies has expanded to include innovative companies, most notably pre-revenue biopharmaceutical companies. At the same time, substantial investments in digital healthcare, fueled by the COVID-19 pandemic, adds a new source of listed companies. This Insight focuses on leading unlisted healthcare companies in China, India, and ASEAN that have raised substantial amounts of capital and appear to be candidates for listing.   

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<div>
<p><a href="https://www.smartkarma.com/entities/jd-health-international" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> is the largest online healthcare platform and the largest online retail pharmacy by revenue in China in 2019, according to Frost &amp; Sullivan.</p>
<div><p>At the proposed IPO price range of HK$62.80-70.58 per share, JD Health will have a market cap of $25.3-28.5 billion. At the mid-point of the IPO price range, the total proceeds are HK$25,469 million ($3.3 billion). Six cornerstone investors will subscribe for $1.35 billion worth of the offer shares. The cornerstone investors include GIC, Hillhouse Capital and BlackRock. </p></div>
</div><div><div><div class="content-highlight"><p>In <a href="https://www.smartkarma.com/insights/jd-health-ipo-initiation-e-ppointments" target="_blank" data-smartkarma-citation="insights:45106" rel="noopener">JD Health IPO Initiation: E-Ppointments</a>, we opined that JD Health’s fundamentals suggest that it is an attractive play on China’s online healthcare platform industry. In <a href="https://www.smartkarma.com/insights/jd-health-ipo-phip-new-data-points-and-peer-comparison" target="_blank" data-smartkarma-citation="insights:45377" rel="noopener">JD Health IPO: PHIP New Data Points and Peer Comparison</a>, we stated that the new data points disclosed in the PHIP along with our peer analysis reinforce our view that JD Health has attractive fundamentals. Overall, we would participate in the IPO due to an attractive IPO price range.</p></div></div></div>


JD Health (6618 HK) is the largest online healthcare platform and the largest online retail pharmacy by revenue in China in 2019, according to Frost &amp; Sullivan.
At the proposed IPO price range of HK$62.80-70.58 per share, JD Health will have a market cap of $25.3-28.5 billion. At the mid-point of the IPO price range, the total proceeds are HK$25,469 million ($3.3 billion). Six cornerstone investors will subscribe for $1.35 billion worth of the offer shares. The cornerstone investors include GIC, Hillhouse Capital and BlackRock. 
In JD Health IPO Initiation: E-Ppointments, we opined that JD Health’s fundamentals suggest that it is an attractive play on China’s online healthcare platform industry. In JD Health IPO: PHIP New Data Points and Peer Comparison, we stated that the new data points disclosed in the PHIP along with our peer analysis reinforce our view that JD Health has attractive fundamentals. Overall, we would participate in the IPO due to an attractive IPO price range.

Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<p><a href="https://www.smartkarma.com/entities/jd-health-international" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> , the largest online healthcare platform and retail pharmacy in China has filed for an IPO to list its shares on the Hong Kong Stock Exchange. Reuters reported today that according to a term sheet obtained by them, JD Health is seeking to raise up to US$3.5bn by selling 381.9m shares at an indicative price range of HK$62.8-70.58 per share.</p><p>The greenshoe option includes the sale of further 15% of the company’s shares which would raise the total IPO proceeds to about US$4bn. The initial size of the deal represents 12.2% of JD Health’s enlarged share capital and at the midpoint of the IPO price of HK$66.69 per share, the company will have a valuation of US$25.6bn.</p><table class="table table-striped"><tbody>
<tr><td colspan="2" style="width: 240.0pt;"><p style="text-align: center;"><strong>JD Health International IPO Details</strong></p></td></tr>
<tr>
<td style="width: 180.0pt;"><p>No. of Shares Issued (m)</p></td>
<td style="width: 60.0pt;"><p style="text-align: right;">381.9</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>IPO Price (HK$)</p></td>
<td style="width: 60.0pt;"><p style="text-align: right;">62.8-70.58</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Offer as a % Total Outstanding Shares</p></td>
<td style="width: 60.0pt;"><p style="text-align: right;">12.20%</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Total Shares Outstanding (m)</p></td>
<td style="text-align: right; width: 60pt;"><p>         3,130.3</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Gross Proceeds (HK$m)</p></td>
<td style="text-align: right; width: 60pt;"><p>      25,468.9</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Gross Proceeds (US$m)</p></td>
<td style="text-align: right; width: 60pt;"><p>         3,280.8</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Market Capitalisation (HK$m)</p></td>
<td style="text-align: right; width: 60pt;"><p>    208,761.6</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Market Capitalisation (US$m)</p></td>
<td style="text-align: right; width: 60pt;"><p>      26,891.6</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Enterprise Value (HK$m)</p></td>
<td style="text-align: right; width: 60pt;"><p>    199,039.3</p></td>
</tr>
<tr>
<td style="width: 180.0pt;"><p>Enterprise Value (US$m)</p></td>
<td style="text-align: right; width: 60pt;"><p>      25,639.2</p></td>
</tr>
</tbody></table><div class="content-caption"><em>Source: Company Disclosures, Reuters, LSR (gross proceeds, market cap and EV are based on the midpoint of the IPO price of HK$66.69 per share, EV is after adjusting for net cash as of Sep 2020)</em></div><p><em>Read our previous insights on the company's IPO:</em></p><p><a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-poised-to-benefit-from-structural-changes-in-healthcare-in-china-and-the-pandemic" target="_blank" data-smartkarma-citation="insights:44220" rel="noopener">JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic</a> </p><p><a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-peer-comparison-reveals-jd-health-s-financials-are-stronger-than-competition" target="_blank" data-smartkarma-citation="insights:44876" rel="noopener">JD Health Pre-IPO: Peer Comparison Reveals JD Health’s Financials Are Stronger than Competition</a> </p><p><a href="https://www.smartkarma.com/insights/jd-health-ipo-phip-data-re-affirms-our-positive-view-on-the-company" target="_blank" data-smartkarma-citation="insights:45425" rel="noopener">JD Health IPO: PHIP Data Re-Affirms Our Positive View on the Company</a> </p>

JD Health (6618 HK) , the largest online healthcare platform and retail pharmacy in China has filed for an IPO to list its shares on the Hong Kong Stock Exchange. Reuters reported today that according to a term sheet obtained by them, JD Health is seeking to raise up to US$3.5bn by selling 381.9m shares at an indicative price range of HK$62.8-70.58 per share.The greenshoe option includes the sale of further 15% of the company’s shares which would raise the total IPO proceeds to about US$4bn. The initial size of the deal represents 12.2% of JD Health’s enlarged share capital and at the midpoint of the IPO price of HK$66.69 per share, the company will have a valuation of US$25.6bn.
JD Health International IPO Details

No. of Shares Issued (m)
381.9


IPO Price (HK$)
62.8-70.58


Offer as a % Total Outstanding Shares
12.20%


Total Shares Outstanding (m)
         3,130.3


Gross Proceeds (HK$m)
      25,468.9


Gross Proceeds (US$m)
         3,280.8


Market Capitalisation (HK$m)
    208,761.6


Market Capitalisation (US$m)
      26,891.6


Enterprise Value (HK$m)
    199,039.3


Enterprise Value (US$m)
      25,639.2

Source: Company Disclosures, Reuters, LSR (gross proceeds, market cap and EV are based on the midpoint of the IPO price of HK$66.69 per share, EV is after adjusting for net cash as of Sep 2020)Read our previous insights on the company's IPO:JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic JD Health Pre-IPO: Peer Comparison Reveals JD Health’s Financials Are Stronger than Competition JD Health IPO: PHIP Data Re-Affirms Our Positive View on the Company 

JD Health IPO: Attractive Even at High End on Cheapness and Gearing to Healthcare Transformation

China

Ping An Healthcare and Technology Company Limited provides health care software solutions. The Company offers mobile platform for online consultation, hospital referral and appointment, health management, and wellness interaction services, as well as connects consumers and patients with health care resources. Ping An Healthcare and Technology serves customers in China.

Ping An Healthcare and Technology (1833 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ping An Healthcare and Technology (1833 HK)

JD Health (京东健康) IPO Trading - Looking to Be a Solid Debut

JD Health (6618 HK) raised US$3.5bn in its Hong Kong IPO, priced at HK$70.58 per share, at the top-end of its price range.

Zhen Zhou, Toh

JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions

JD Health's IPO bookbuild will likely close a day early. In this note, we take a look at Ali Health’s 1H FY2020 results and the prospects of early...

Zhen Zhou, Toh

Asian Healthcare - Coming of Age

This Smartkarma Originals Insight highlights 20 leading unlisted healthcare companies in Asia, mainly in digital healthcare and biopharma, that are...

Kemp Dolliver, CFA

JD Health IPO: Valuation Insights

At the proposed IPO price range of HK$62.80-70.58 per share, JD Health will have a market cap of $25.3-28.5 billion. Overall, we would participate...

Arun George

JD Health IPO: Attractive Even at High End on Cheapness and Gearing to Healthcare Transformation

Reuters reported today that according to a term sheet obtained by them, JD Health is seeking to raise up to US$3.5bn by selling 381.9m shares at an...

Shifara Samsudeen, FCMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)